Dr. Mowei Kong, MD, is a seasoned medical professional with a rich background in endocrinology, metabolism, oncology, and cardiovascular diseases. He previously served as a clinical physician at Guiqian International Hospital and is currently engaged in basic research at Southwest Medical College. Dr. Kong's expertise spans Type 2 Diabetes, insulin resistance, obesity, gastrointestinal and cardiac tumors, and coronary heart disease. Some notable works include studies on CTRP6's role in digestive system tumors and GLP-1 receptor agonists' effects on lipotoxicity.
His experience in these areas highlights his ability to analyze signal transduction pathways, identify new therapeutic targets, and translate basic scientific research into clinical applications. Dr. Kong's comprehensive experience in both clinical practice and research enables him to provide valuable insights and advancements in the understanding and treatment of cancer and related conditions.
Dr. Chunxiang Zhang is a distinguished cardiologist and academic leader with extensive international experience in cardiology and oncology. He holds a Doctor of Cardiology degree and completed his postdoctoral fellowship in cardiovascular pharmacology in the US. Currently serving as the Deputy Secretary of the Party Committee and President of Southwest Medical University, he also directs the Key Laboratory of the Ministry of Education. His career spans over three decades, including ten years in top cardiology departments in China and 22 years in the US, where he held prestigious positions at the University of Tennessee and Rush University. Dr. Zhang's research delves into the molecular mechanisms of tumorigenesis, inflammation, and cancer therapies, with notable work on tetraspanins in digestive system cancers and innovative therapeutic strategies. His comprehensive research and publications provide valuable insights into signaling pathways, biomarkers, and clinical implications, making him a key figure in advancing cancer treatment and understanding.
